From Heparin to Gpiib/Iiia Inhibitors and Doacs: The Revolution in Antithrombotic Therapy
Year: 2025
Type: article
Abstract: Acute Coronary Syndrome (ACS) remains a significant global burden, necessitating ongoing innovation in therapeutic strategies. Over the past three decades, landmark clinical trials such as PRISM, PRISM-PLUS, PARAGON A, PARAGON B, PURSUIT, and GUSTO IV-ACS have shaped our understanding and management of ACS. These studies provided pivotal data on the role of antithrombotic agents, glycoprotein IIb/IIIa inhibitors, and tailored therapeutic approaches in high-risk populations. This review explores the design, outcomes, and impact of these foundational trials while tracing the evolution of ACS management to current guidelines and practices. Furthermore, we analyze how the insights from these trials have influenced contemporary clinical decision-making and identify the gaps they left for future research. By revisiting these landmark studies, we aim to contextualize their legacy and discuss their relevance in the era of precision medicine and novel therapeutic modalities.
Authors: Diego Alejandro Ramírez López, Donaldo Emiliano Silva López, Sofía Rolon González, Mario Arturo Márquez Reyes, Karla Daniela Huerta Ortiz, Jesús Emilio Müller Gómez
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6968089732
FWCI:
Cites:
Cited by:
Related to: